Department of Medicine, Dow International Medical College, Dow University of Health Sciences, Karachi, 74200, Pakistan.
Department of Medicine, King Edward Medical University/Mayo Hospital, Lahore, 54000, Pakistan.
Endocrine. 2024 Jan;83(1):51-59. doi: 10.1007/s12020-023-03479-4. Epub 2023 Aug 11.
Polycystic ovarian syndrome (PCOS) is the heightened ovarian dysfunction associated with excessive androgen production, manifesting with hirsutism, abnormal menstrual cycle, and polycystic ovaries. In this systematic review and meta-analysis, the effect of resveratrol on laboratory parameters of PCOS women will be assessed.
An electronic search via PubMed, Cochrane Library, and Scopus was performed up to February 2023 for randomized controlled trials conforming to our pre-specified outcomes. A random-effects model was utilized, with cohorts compared using mean differences.
Three randomized controlled trials (RCTs) were included, reporting 84 patients receiving resveratrol, and 85 patients receiving placebo. It was observed that resveratrol significantly improved prolactin levels (P = 0.02), acne scores (P = 0.008), and total cholesterol (P = 0.02). However, there were no significant improvements observed with respect to total testosterone, follicle stimulating hormone (FSH), lutenizing hormone (LH), body mass index (BMI), hirsutism scores, triglycerides, high-density lipoprotein (HDL), and low-density lipoprotein (LDL).
As per the results of our analysis, resveratrol demonstrates mild therapeutic potential for the sufferers of PCOS, and cannot replace the current established treatment guidelines. However, further comprehensive RCTs are required in order to assess the efficacy in long-term dosing and the safety profile of the use of resveratrol.
多囊卵巢综合征（PCOS）是一种与雄激素过度产生相关的卵巢功能障碍，表现为多毛症、月经周期异常和多囊卵巢。在这项系统评价和荟萃分析中，将评估白藜芦醇对多囊卵巢综合征女性实验室参数的影响。
通过 PubMed、Cochrane 图书馆和 Scopus 进行电子检索，检索截至 2023 年 2 月符合我们预先指定结局的随机对照试验。采用随机效应模型，使用均数差比较队列。
纳入了 3 项随机对照试验（RCT），报告了 84 例接受白藜芦醇治疗的患者和 85 例接受安慰剂治疗的患者。结果表明，白藜芦醇显著改善了催乳素水平（P=0.02）、痤疮评分（P=0.008）和总胆固醇（P=0.02）。然而，在总睾酮、卵泡刺激素（FSH）、黄体生成素（LH）、体重指数（BMI）、多毛症评分、甘油三酯、高密度脂蛋白（HDL）和低密度脂蛋白（LDL）方面，没有观察到显著改善。
根据我们的分析结果，白藜芦醇对 PCOS 患者具有一定的治疗潜力，但不能替代当前的既定治疗指南。然而，需要进一步进行全面的 RCT 来评估长期剂量使用的疗效和白藜芦醇使用的安全性。
